North Central London
Joint Formulary
 
back
5 Infections

Prescribing of systemic antimicrobials is 'protected'. All prescribing MUST be in accordance with the Trust Antimicrobial Policy and in conjunction with local antimicrobial guideline:

05-03-01 Other antiretrovirals

Dolutegravir
Formulary

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • HIV medicine only
  • RNOH:
    • Non-formulary  
  • UCLH:
  • WH:
    • Non-formulary
Link  NHSE B06/P/a: Dolutegravir for treatment of HIV1 in adults and adolescents

GP - Red View adult BNF  View SPC online  View childrens BNF  HCD
Dolutegravir + Abacavir + Lamivudine Triumeq®
Formulary

Approved for HIV in line with NHSE Commissioning Policy B06/P/a.

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • HIV medicine only
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
Link  NHSE B06/P/a: Dolutegravir for treatment of HIV1 in adults and adolescents

GP - Red View adult BNF  View SPC online  View childrens BNF  HCD
Dolutegravir + Rilpivirine Juluca®
Formulary

Approved for HIV in line with NHSE Commissioning Policy 200210P.

Provider notes

  • NMUH:
    • Restricted to HIV team ONLY
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
Link  NHSE 200210P: Dolutegravir-rilpivirine for treating HIV-1 in adults

GP - Red View adult BNF  View SPC online  View childrens BNF  HCD
Enfuvirtide
Restricted

Provider notes

  • NMUH:
    • To be used in accordance with the London HIV consortium BHIVA guidelines
    • For HIV team only
    • Patients currently benefiting from enfuvirtide in their combination therapy should continue to receive enfuvirtide without interruption. Current benefit is defined as patients whose viral load is either undetectable or remaining below their pre-enfuvirtide baseline level. Patients whose current viral load has substantially rebounded or returned to their baseline level when their first used enfuvirtide and who have a strong CD4 count, are likely to have developed or be developing resistance to enfuvirtide. Enfuvirtide is also unlikely to be having antiretroviral activity, and these patients should consider stopping the enfuvirtide in their combination, with close monitoring BHIVA Guidelines - Treatment of HIV-1 infected adults with antiretroviral therapy
  • RFL:
    • HIV medicine only
  • RNOH:
    • Non-formulary  
  • UCLH:
  • WH:
    • Non-formulary

Restricted Drug GP - Red View adult BNF  View SPC online  View childrens BNF  HCD
Maraviroc
Restricted

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • HIV medicine only
  • RNOH:
    • Non-formulary  
  • UCLH:
  • WH:
    • Non-formulary

Restricted Drug GP - Red View adult BNF  View SPC online  View childrens BNF  HCD
Raltegravir
Restricted

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • HIV medicine only
  • RNOH:
    • Restricted for use in accordance with RNOH Sharps Policy and Inoculation Management (see policy)
  • UCLH:
  • WH:
    • For TB / HIV clinic and post-exposure prophylaxis
Link  RNOH: Sharps Policy and Inoculation Management

Restricted Drug GP - Red View adult BNF  View SPC online  View childrens BNF  HCD